Working… Menu

Mometasone and Markers of Airway Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00711165
Recruitment Status : Completed
First Posted : July 8, 2008
Last Update Posted : July 8, 2008
Information provided by:
Creighton University

Brief Summary:
A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.

Condition or disease Intervention/treatment Phase
Asthma Drug: Placebo Drug: Mometasone Furoate Phase 4

Detailed Description:
Patients with asthma and not treated with anti-inflammatory medications were studied. This was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1 and nitrates/nitrites and pH in exhaled breath condensate.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effects of Mometasone on Markers of Airway Inflammation
Study Start Date : August 2005
Actual Primary Completion Date : April 2006
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo, 2 puffs, bid
Drug: Placebo
2 puffs, qd

Experimental: Memetasone
Drug: Mometasone Furoate
400 mcg, qd for 8 weeks
Other Name: asmanex

Primary Outcome Measures :
  1. Exhaled Nitric Oxide [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Airway Reactivity [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Asthma
  • non-smoker
  • FEV1 of at least 60% predicted

Exclusion Criteria:

  • Pregnancy or lactation
  • Corticosteroid use in past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00711165

Layout table for location information
United States, Nebraska
Creighton University Medical Center
Omaha, Nebraska, United States, 68131
Sponsors and Collaborators
Creighton University
Layout table for investigator information
Principal Investigator: Thomas B Casale, MD Creighton University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Thomas B. Casale, MD, Creighton University Identifier: NCT00711165    
Other Study ID Numbers: Mometasone TBC
First Posted: July 8, 2008    Key Record Dates
Last Update Posted: July 8, 2008
Last Verified: July 2008
Keywords provided by Creighton University:
Nitric Oxide
Exhaled Breath Condensate
Methacholine Challenge
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents